Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Med Sci ; 18(12): 2500-2509, 2021.
Article in English | MEDLINE | ID: mdl-34104081

ABSTRACT

Background: B-type natriuretic peptide (BNP) is a well-known predictor for prognosis in patients with cardiac and renal diseases. However, there is a lack of studies in patients with advanced hepatic disease, especially patients who underwent liver transplantation (LT). We evaluated whether BNP could predict the prognosis of patients who underwent LT. Material and Methods: The data from a total of 187 patients who underwent LT were collected retrospectively. The serum levels of BNP were acquired at four time points, the pre-anhepatic (T1), anhepatic (T2), and neohepatic phases (T3), and on postoperative day 1 (T4). The patients were dichotomized into survival and non-survival groups for 1-month mortality after LT. Combined BNP (cBNP) was calculated based on conditional logistic regression analysis of pairwise serum BNP measurements at two time points, T2 and T4. The area under the receiver operating characteristic curve (AUROC) was analyzed to determine the diagnostic accuracy and cut-off value of the predictive models, including cBNP. Results: Fourteen patients (7.5 %) expired within one month after LT. The leading cause of death was sepsis (N = 9, 64.3 %). The MELD and MELD-Na scores had an acceptable predictive ability for 1-month mortality (AUROC = 0.714, and 0.690, respectively). The BNPs at each time point (T1 - T4) showed excellent predictive ability (AUROC = 0.864, 0.962, 0.913, and 0.963, respectively). The cBNP value had an outstanding predictive ability for 1-month mortality after LT (AUROC = 0.976). The optimal cutoff values for cBNP at T2 and T4 were 137 and 187, respectively. Conclusions: The cBNP model showed the improved predictive ability for mortality within 1-month of LT. It could help clinicians stratify mortality risk and be a useful biomarker in patients undergoing LT.


Subject(s)
End Stage Liver Disease/mortality , Liver Transplantation/adverse effects , Natriuretic Peptide, Brain/blood , Postoperative Complications/mortality , Adult , Aged , Biomarkers/blood , End Stage Liver Disease/blood , End Stage Liver Disease/surgery , Female , Hospital Mortality , Humans , Male , Middle Aged , Postoperative Complications/etiology , Postoperative Period , Predictive Value of Tests , Preoperative Period , Prognosis , ROC Curve , Retrospective Studies , Risk Assessment/methods , Treatment Outcome
2.
Int J Med Sci ; 17(1): 82-88, 2020.
Article in English | MEDLINE | ID: mdl-31929741

ABSTRACT

Background. Acute kidney injury (AKI) is one of the common complications after living donor liver transplantation (LDLT) and is associated with increased mortality and morbidity. The prognostic nutritional index (PNI) has been used as a predictive model for postoperative complications. Here, we create a new predictive model based on the PNI and compared its predictive accuracy to other models in patients who underwent LDLT. Material and Methods: The data from 423 patients were collected retrospectively. The patients were dichotomized into the non-AKI and the AKI groups. Multivariate adjustment for significant postoperative variables based on univariate analysis was performed. A new predictive model was created using the results from logistic regression analysis, dubbed the modified-PNI model (mPNI). The area under the receiver operating characteristic curve (AUC) was generated to determine the diagnostic accuracy and cutoff value of individual models. The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to investigate diagnostic improvement by the mPNI. Results: Fifty-four patients (12.7 %) were diagnosed with AKI within 1-week after LDLT. The mPNI had the highest predictive accuracy (AUC = 0.823). The model of end-stage liver disease (MELD) scores and PNI were 0.793 and 0.749, respectively, and the INR and serum bilirubin were 0.705 and 0.637, respectively. The differences in the AUCs were statistically significant among the mPNI, PNI, INR, and serum bilirubin. The cutoff value for mPNI was 8.7. The NRI was 10.4% and the IDI was 3.3%. Conclusions: The mPNI predicted AKI within 1-week better than other scoring systems in patients who underwent LDLT. The recommended cutoff value of mPNI is 8.7.


Subject(s)
Acute Kidney Injury/therapy , Liver Diseases/therapy , Liver Transplantation , Nutrition Assessment , Acute Kidney Injury/epidemiology , Acute Kidney Injury/pathology , Female , Humans , Liver Diseases/epidemiology , Liver Diseases/physiopathology , Living Donors , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Severity of Illness Index
3.
J Biomed Mater Res B Appl Biomater ; 105(4): 828-835, 2017 05.
Article in English | MEDLINE | ID: mdl-26804634

ABSTRACT

This article addresses the effects of glycerol (GLY) concentrations on the mechanical properties of calcium polyphosphate (CPP) bone substitute structures manufactured using binder jetting additive manufacturing. To achieve this goal, nine types of water-based binder solutions were prepared with 10, 12.5, and 15 wt % GLY liquid-binding agent, mixed, respectively, with 0, 0.75, and 1.5 wt % ethylene glycol diacetate (EGD) flow enhancer. The print quality of each of the solutions was established quantitatively using an image processing algorithm. The print quality analysis narrowed down the solutions to three batches containing 1.5 wt % EGD and variable amount of GLY. These solutions were used to manufacture porous CPP bone substitute samples, which were characterized physically to determine shrinkage, porosity, microstructure, and compression strength. The 12.5 wt % GLY, 1.5 wt % EGD solution resulted in the highest mechanical strength after sintering (34.6 ± 5.8 MPa), illustrating similar mechanical properties when compared to previous studies (33.9 ± 6.3 MPa) of additively manufactured CPP bone substitutes using a commercially available binder. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 828-835, 2017.


Subject(s)
Bone Substitutes/chemistry , Compressive Strength , Glycerol/chemistry , Polyphosphates/chemistry , Printing, Three-Dimensional , Ethylene Glycols/chemistry , Porosity
4.
Anat Cell Biol ; 43(1): 25-35, 2010 Mar.
Article in English | MEDLINE | ID: mdl-21190002

ABSTRACT

Vitamin C, one of essential micronutrients, has been reported to modulate the humoral immune responses in some mammals. We investigated whether vitamin C might modulate this response in mice by directly affecting B cells. Splenic B cells were isolated and activated by CD40- and B cell receptor-ligation in vitro. The cells were cultured with a pretreatment of vitamin C from 0 to 1 mM of concentrations. Vitamin C slightly increased apoptosis of B cells dose-dependently and behaved as an antioxidant. We found that in vivo administration of vitamin C by intraperitoneal injection affected isotype switching as previously reported: the titer of antigen-specific IgG1 antibody was decreased, while that of IgG2a was unaffected. Somewhat different from those observed in vivo, in vitro exposure to vitamin C slightly decreased isotype switching to IgG1 and increased isotype switching to IgG2a. Pretreatment with vitamin C in the safe range did not affect either proliferation of cultured B cells or the expression of CD80 and CD86 in those cells. Taken together, in vivo results suggest that vitamin C acts to modulate isotype switching in the mouse. However, because of our in vitro results, we suggest that the modulation exerted by vitamin C in vivo is by indirectly affecting B cells, perhaps by directly influencing other immune cells such as dendritic cells.

5.
Immunobiology ; 214(4): 311-20, 2009.
Article in English | MEDLINE | ID: mdl-19327547

ABSTRACT

Vitamin C is an essential micronutrient, which has been implicated in various biological processes, including immune response. In fact, in vivo administration of vitamin C modulates T cell proliferation and cytokine secretion. In this study, we analyzed the mechanism by which mouse T cells take up vitamin C, and whether this uptake directly affected T cell functions. T cells internalized more vitamin C when they were activated, due to enhanced glucose transporter (GLUT)-1 and GLUT-3 expression that persisted up to 48 h after activation. Blocking oxidation of ascorbic acid (the reduced form of vitamin C) in the culture medium with 1,4-dithio-threitol (DTT) almost completely inhibited the enhanced vitamin C uptake. The presence of vitamin C at low concentrations during in vitro T cell activation did not affect proliferation or cytokine secretion (IFN-gamma, TNF-alpha, or IL-4) in response to PMA/ionomycin. In contrast, high concentrations (0.25-0.5 mM) of vitamin C lowered cell viability, reduced thymidine uptake, and decreased cytokine secretion. In conclusion, activated T cells upregulated GLUT-1 and -3 to increase vitamin C uptake. They took up vitamin C mostly in its oxidized form, rarely in its reduced form. Application of vitamin C to T cells in vitro did not recapitulate previously reported in vivo responses to vitamin C, suggesting that in vivo, vitamin C modulates T cells indirectly through other components of the microenvironment.


Subject(s)
Ascorbic Acid/metabolism , Dehydroascorbic Acid/metabolism , Glucose Transporter Type 1/metabolism , Glucose Transporter Type 3/metabolism , T-Lymphocytes/metabolism , Animals , Ascorbic Acid/chemistry , Ascorbic Acid/immunology , Biological Transport/drug effects , Cell Proliferation/drug effects , Cell Survival/immunology , Cytokines/antagonists & inhibitors , Cytokines/metabolism , Dehydroascorbic Acid/chemistry , Dehydroascorbic Acid/immunology , Dithiothreitol/pharmacology , Glucose Transporter Type 1/genetics , Glucose Transporter Type 1/immunology , Glucose Transporter Type 3/genetics , Glucose Transporter Type 3/immunology , Immunomagnetic Separation , Ionomycin/pharmacology , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred BALB C , Oxidation-Reduction/drug effects , T-Lymphocytes/immunology , Tetradecanoylphorbol Acetate/pharmacology , Thymidine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...